Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Science Signaling|December 25, 2014
Systematic identification of signaling pathways with potential to confer anticancer drug resistanceColin A Martz, Kathleen A Ottina, Katherine R Singleton, et al.
Cancer Discovery|October 10, 2013
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2Michael P O'Connell, Katie Marchbank, Marie R Webster, et al.
Cancer Discovery|September 14, 2018
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaShelly Kalaora, Yochai Wolf, Tali Feferman, et al.
Cancer Discovery|November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibitionNikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
Oncoimmunology|July 7, 2017
Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot studyYong Qin, Mariana Petaccia de Macedo, Alexandre Reuben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2022
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305Krista Kinneer, Philipp Wortmann, Zachary A Cooper, et al.
The Lancet. Oncology|August 7, 2022
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trialNeeta Somaiah, Anthony P Conley, Edwin Roger Parra, et al.
Oncoimmunology|November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanomaMichael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.
Nature Genetics|February 10, 2015
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesLuping Lin, Amit J Sabnis, Elton Chan, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Pageof 9